Johns Hopkins has several clinical trials dealing with psilocybin from the effects of it ramping down the brains ego centers, as well as relieving major depressive orders for up to a year after the session. Receiving regulatory approval back in 2000 to continue psychedelic research they were the first to be granted permission in the United States with healthy volunteers that had no existing psychedelic experience.
Yale has an impressive resume of psychedelic and empathogenic studies helping to continue push our culture forward. While taking some notes from Johns Hopkins studies Yale has used psilocybin to test the efficacy of the compound to induce neuroplasticity aiding treatment of depression, as well as the potential for psilocybin to help with OCD symptoms. Aside from psilocybin Yale has also been testing MDMA and how it reacts with the prefrontal cortex and amygdala in patients with PTSD.
Washington University has been working with psilocybin and mapping its effects on neurogenesis to combat depression. They are partnered with the Usona Institute which is a not for profit medical research institution. They are also partnered with The Healthy Mind Lab working with the dissociative ketamine to optimize its clinical response and develop a deeper understanding of neurobiology.
4. Basel University, Switzerland
Basel University has an array of compounds in clinical research from psilocybin and LSD to MDMA as well. LSD is a popular choice at this university, as its being investigated as a medication for patients with anxiety, major depression, and even cluster headaches. They are also testing the use of psychedelic substances on emotional processing in humans and their effects on dopamine and seratonin.
5. Stanford University
Stanford University is also conducting several research trials ranging from ketamine, to mdma, and psilocybin. Stanford is using ketamine to explore its interaction with patients exhibiting symptoms of OCD and the rapid improvements it can make to aid them. They are also testing the reward circuits of the brain through mdma trials having participants monitored through an imaging session during and after the trials. With psilocybin they are also testing its ability to help those with major depressive disorders.